We have acquired development and market rights of GBT-201 in 28 countries in the Asia Pacific region including Korea, Japan, and Australia, and have also secured market rights in the United States and Canada through a joint venture company, ReGenTree, LLC.
DES in the US, Canada & AsiaPac 28 Countries
NK in the US, Canada & AsiaPac 28 Countries
Orphan Designation Status in the US
DES in the US, Canada & AsiaPac 28 Countries
NK in the US, Canada & AsiaPac 28 Countries
Orphan Designation Status in the US
· DES : Dry Eye Syndrome
· NK : Neurotrophic Keratopathy
· NK : Neurotrophic Keratopathy